Suministro de Omalizumab (DOE), Nilotinib (DOE), Eltrombopag (DOE), Dabrafenib (DOE), Secukinumab (DOE), Pazopanib (DOE), Trametinib (DOE), Everolimus (DOE) y Midostaurina (DOE)
TED · 541192-2026Award notice · modificationawardedNo deadline given
Buyer
NameOSAKIDETZA - Servicio Vasco de Salud - Organización Central
CountryES
Published2026-08-05
Deadline—
Value
Estimated—
Awarded€4,686,183 · 4,686,182.6 EUR
WinnerNOVARTIS FARMACEUTICA, S.A.
Who already wins at this buyer
Firms with recorded awards from OSAKIDETZA - Servicio Vasco de Salud - Organización Central in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ASTRAZENECA FARMACEUTICA SPAIN, S.A. | 6 | €14,614,191 | 2026-10-22 |
| PFIZER, S.L. | 5 | €67,637,810 | 2026-10-09 |
| EDWARDS LIFESCIENCIES, S.L. | ABBOTT MEDICAL ESPAÑA SA | MEDTRONIC IBÉRICA, S.A. | BOSTON SCIENTIFIC IBÉRICA, S.A. | MERCÉ V. ELECTROMEDICINA, S.L. | PALEX MEDICAL | SAGITTAE MEDICAL S.L | SERMEBI 97 SL | 5 | €40,141,054 | 2026-09-18 |
| TAKEDA FARMACÉUTICA ESPAÑA, S.A. | 5 | €10,796,370 | 2026-10-16 |
| ROCHE FARMA, S.A. UNIPERSONAL | 4 | €130,837,823 | 2026-09-08 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Suministro de Omalizumab (DOE), Nilotinib (DOE), Eltrombopag (DOE), Dabrafenib (DOE), Secukinumab (DOE), Pazopanib (DOE), Trametinib (DOE), Everolimus (DOE) y Midostaurina (DOE)
Similar tenders
Closest by meaning — across languages, via embeddings.